Terns Pharmaceuticals, Inc. (TERN)Healthcare | Biotechnology | Foster City, United States | NasdaqGS
52.65 USD
-0.04
(-0.076%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 52.61 -0.04 (-0.040%) ⇩ (April 17, 2026, 7:37 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:29 p.m. EDT
Terns Pharmaceuticals (TERN) is trading at its 52-week high following a massive catalyst: a $6.7 billion acquisition by Merck. This deep-value arb opportunity, originally priced for failure, has flipped to a massive winner as the company's leukemia pipeline is validated. The technicals are flawless near term, and the options market is aggressively betting on further upside, though the primary move is likely priced in. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.030219 |
| AutoARIMA | 0.241763 |
| AutoETS | 0.241764 |
| MSTL | 0.262579 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 3.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.535 |
| Excess Kurtosis | -0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.091 |
| Market Cap | 6,076,515,328 |
| Forward P/E | -35.78 |
| Beta | -0.38 |
| Website | https://www.ternspharma.com |
As of April 18, 2026, 10:29 p.m. EDT: Options flow shows overwhelmingly bullish positioning in calls for the near term. May expiration shows massive Open Interest (OI) walls at strikes 50.0, 55.0, and 60.0, with 99% positioning in Out-of-the-Money calls. Long strangles are concentrated far OTM on the upside. While distant expirations (Jan 2027+) show some OTM put selling, the volume and OI in near-term calls (May/June) are significantly higher than puts, indicating a high-conviction floor offer and potential upside trade by speculators.
| Attribute | Value |
|---|---|
| 52 Week Change | 18.428043 |
| Address1 | 1,065 East Hillsdale Boulevard |
| Address2 | Suite 100 |
| All Time High | 53.19 |
| All Time Low | 1.45 |
| Ask | 67.49 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.8 - Hold |
| Average Daily Volume10 Day | 9,228,200 |
| Average Daily Volume3 Month | 5,481,458 |
| Average Volume | 5,481,458 |
| Average Volume10Days | 9,228,200 |
| Beta | -0.376 |
| Bid | 37.96 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 8.961 |
| City | Foster City |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 52.65 |
| Current Ratio | 62.409 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 52.72 |
| Day Low | 52.62 |
| Debt To Equity | 0.091 |
| Display Name | Terns Pharmaceuticals |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -110,034,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -45.972 |
| Enterprise Value | 5,058,451,968 |
| Eps Current Year | -1.06143 |
| Eps Forward | -1.47143 |
| Eps Trailing Twelve Months | -1.03 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 275 4254 |
| Fifty Day Average | 45.9978 |
| Fifty Day Average Change | 6.6522026 |
| Fifty Day Average Change Percent | 0.14462002 |
| Fifty Two Week Change Percent | 1,842.8043 |
| Fifty Two Week High | 53.19 |
| Fifty Two Week High Change | -0.5399971 |
| Fifty Two Week High Change Percent | -0.01015223 |
| Fifty Two Week Low | 2.37 |
| Fifty Two Week Low Change | 50.280003 |
| Fifty Two Week Low Change Percent | 21.215193 |
| Fifty Two Week Range | 2.37 - 53.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 115,123,704 |
| Forward Eps | -1.47143 |
| Forward P E | -35.78152 |
| Free Cashflow | -55,480,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00529 |
| Held Percent Institutions | 1.09459 |
| Implied Shares Outstanding | 115,413,392 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. |
| Long Name | Terns Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 6,076,515,328 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_558294166 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -96,207,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,076,515,088 |
| Number Of Analyst Opinions | 8 |
| Open | 52.72 |
| Operating Cashflow | -82,176,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 525 5535 |
| Post Market Change | -0.040000916 |
| Post Market Change Percent | -0.07597514 |
| Post Market Price | 52.61 |
| Post Market Time | 1,776,469,036 |
| Previous Close | 52.69 |
| Price Eps Current Year | -49.602898 |
| Price Hint | 2 |
| Price To Book | 5.87546 |
| Profit Margins | 0.0 |
| Quick Ratio | 62.091 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.8 |
| Region | US |
| Regular Market Change | -0.0399971 |
| Regular Market Change Percent | -0.0759102 |
| Regular Market Day High | 52.72 |
| Regular Market Day Low | 52.62 |
| Regular Market Day Range | 52.62 - 52.72 |
| Regular Market Open | 52.72 |
| Regular Market Previous Close | 52.69 |
| Regular Market Price | 52.65 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 6,348,187 |
| Return On Assets | -0.0991 |
| Return On Equity | -0.14228 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 115,413,392 |
| Shares Percent Shares Out | 0.117 |
| Shares Short | 13,505,870 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 16,616,789 |
| Short Name | Terns Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1171 |
| Short Ratio | 1.72 |
| Source Interval | 15 |
| State | CA |
| Symbol | TERN |
| Target High Price | 58.0 |
| Target Low Price | 53.0 |
| Target Mean Price | 53.625 |
| Target Median Price | 53.0 |
| Total Cash | 1,018,982,016 |
| Total Cash Per Share | 8.829 |
| Total Debt | 919,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.03 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.1071 |
| Two Hundred Day Average Change | 27.542902 |
| Two Hundred Day Average Change Percent | 1.0970165 |
| Type Disp | Equity |
| Volume | 6,348,187 |
| Website | https://www.ternspharma.com |
| Zip | 94,404 |